T = 296 K.
CCDC no.: 1429765
The crystal structure is shown in the figure. Table 1 contains details on crystal structure and measurement conditions. Table 2 lists the atoms with their coordinates and displacement parameters.
Source of materials
The title compound was synthesized according to a reported procedure [3] . A mixture of 3,5-cyclohexanedione (10 mmol), 3-bromo-4-fluoro-benzaldehyde (10 mmol), mal-*Corresponding author: Jing Song, School of Chemical Engineering, Xi'an University, Xi'an, Shaanxi, China, e-mail: song_jing666@163.com ononitrile (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) were refluxed in ethanol (100 mL) for 2-3 h and then cooled to room temperature. After filtering the precipitate, it was washed with ice-cooled water and ethanol sequentially and then dried under a vacuum.
Experimental details
Hydrogen atoms bonded to C and N were positioned geometrically and refined using a riding model, with C· · · H = 0.97 Å and N· · · H = 0.86 Å. U iso (H) was set to 1.2 times Ueq(C) and Ueq(N).
Comment
The importance of the pyranyl moiety has been well proven as illustrated by a large number of patents for its use as chemotherapeutic agent [4, 5] . A number of biological activities have been associated with it, such as antihypertensive, antiasthemic, analgesic, cardiovascular, platelate aggregation inhibitor and calcium antagonist [6] . With this in mind, some new pyran derivatives have been synthesized in search of better therapeutic agents, by a convenient single pot method [7] . In the crystal structure of the title compound, the pyran ring is folded slightly (dihedral angle C4-C3-C2-C1 = 25°). The plane of the 3-bromo-4-fluoro-phenyl moiety is almost perpendicular to it. The adjacent dimethyl-cyclo-hexen-1-onyl ring adopts a "chair" conformation with an dihedral angle C4-C7-C8-C9 of 33°. Bond lengths and angles are almost in the expected ranges.
